Sunshine Biopharma (SBFM) Non Operating Interest Expenses (2012 - 2024)
Sunshine Biopharma's (SBFM) quarterly Non Operating Interest Expenses came in at $8529.0 in Q4 2024, down 71.67% on a YoY basis from $30110.0 in Q1 2024, and up 3381.22% quarter-over-quarter from $245.0 in Q2 2024.
Powered by 
Analysis
Sunshine Biopharma (SBFM) Non Operating Interest Expenses (2012 - 2024) Analysis & Trends
Sunshine Biopharma (SBFM) has reported Non Operating Interest Expenses for 12 consecutive years, with $8529.0 the latest figure, recorded in Q4 2024.
- For the quarter ending Q4 2024, Non Operating Interest Expenses fell 71.67% year-over-year to $8529.0; the trailing twelve-month figure through Sep 2025 stood at $8529.0 (down 89.28% YoY), and the FY2024 full-year result was $8774.0, down 93.61% from the prior year.
- Non Operating Interest Expenses climbed to $8529.0 in Q4 2024 per SBFM's latest filing, from $245.0 in the prior quarter.
- Across five years, Non Operating Interest Expenses topped out at $195630.0 in Q2 2021 and bottomed at $2.0 in Q3 2022.
- Historically, Non Operating Interest Expenses has averaged $39296.4 across 5 years, with a median of $28328.0 in 2022.
- The sharpest annual moves came in 2022 and 2023: Non Operating Interest Expenses plunged 100.0% in 2022, then surged 1926250.0% in 2023.
- Over 5 years, Non Operating Interest Expenses stood at $105436.0 in 2020, then sank by 65.26% to $36630.0 in 2021, then slipped by 27.53% to $26546.0 in 2022, then rose by 13.43% to $30110.0 in 2023, then slumped by 71.67% to $8529.0 in 2024.
- According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $8529.0, $245.0, and $49181.0 for Q4 2024, Q2 2024, and Q1 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.61 Bn | 38.95 Bn | 2.15 Bn | - |
| 2 | Viatris | 19.18 Bn | 18.30 Bn | 1.46 Bn | 120.70 Mn |
| 3 | Dr Reddys Laboratories | 9.85 Bn | 9.68 Bn | 396.53 Mn | -13.26 Mn |
| 4 | Amneal Pharmaceuticals | 5.48 Bn | 5.35 Bn | 334.51 Mn | - |
| 5 | Bausch Health Companies | 2.36 Bn | 518.87 Mn | 2.10 Bn | 396.00 Mn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | -41.02 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | - |
| 8 | Amphastar Pharmaceuticals | 994.21 Mn | 704.09 Mn | 93.47 Mn | 6.66 Mn |
| 9 | Fennec Pharmaceuticals | 405.56 Mn | 364.31 Mn | 17.15 Mn | 3,000.00 |
| 10 | Sunshine Biopharma | 1.56 Mn | -12.19 Mn | 2.43 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 8,529.00 |
| Jun 30, 2024 | 245.00 |
| Mar 31, 2024 | 49,181.00 |
| Dec 31, 2023 | 30,110.00 |
| Sep 30, 2023 | 38,527.00 |
| Jun 30, 2023 | 3,331.00 |
| Mar 31, 2023 | 41,075.00 |
| Dec 31, 2022 | 26,546.00 |
| Sep 30, 2022 | 2.00 |
| Mar 31, 2022 | 12,864.00 |
| Dec 31, 2021 | 36,630.00 |
| Sep 30, 2021 | 46,849.00 |
| Jun 30, 2021 | 195,630.00 |
| Mar 31, 2021 | 49,711.00 |
| Dec 31, 2020 | 105,436.00 |
| Sep 30, 2020 | 22,094.00 |
| Jun 30, 2020 | 24,219.00 |
| Mar 31, 2020 | 16,356.00 |
| Dec 31, 2019 | 23,415.00 |
| Sep 30, 2019 | 27,847.00 |